Abstract
A short and efficient synthesis of three stereoisomeric and three process impurities of Alalevonadifloxacin mesylate (WCK 2349), a novel anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotic, has been disclosed. The synthesis and characterization of these impurities are discussed in detail to provide access to the reference standards for the impurity profile of the drug substance as well as the drug product. Moreover, systematic analytical method development for stereospecific separation between alalevonadifloxacin mesylate (1) and an enantiomer, WCK 6577 (2) in the presence of other process impurities for accurate quantification using liquid chromatography is also discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
